2019 年第 10 期 第 14 卷

曲美布丁联合复方阿嗪米特对功能性消化不良患者胃蛋白酶原及胃泌素水平的影响

Effect of trimebutine combined with compound azintamide on pepsinogen and gastrin levels in patients with functional dyspepsia

作者：徐斌周进鲁明张伟

英文作者：

单位：232007安徽省淮南市第一人民医院消化内科

英文单位：

关键词：功能性消化不良；曲美布丁；复方阿嗪米特；胃蛋白酶原；胃泌素

英文关键词：

• 摘要：

• 【摘要】目的    观察曲美布丁联合复方阿嗪米特对功能性消化不良（FD）患者胃蛋白酶原及胃泌素水平的影响。方法    以2017年1月至2018年12月安徽省淮南市第一人民医院诊治的140例FD患者为研究对象。采用随机数字表法分为对照组（65例）和观察组（75例）。对照组患者接受复方阿嗪米特治疗，观察组患者接受曲美布丁联合复方阿嗪米特治疗。分析2组患者的临床治疗效果，并比较患者治疗前后血清中胃蛋白酶原、胃泌素、5-羟色胺及生长抑素水平。结果    观察组患者的总有效率明显高于对照组［90.7%（68/75）比72.3%（47/65）］，差异有统计学意义（P<0.05）。治疗后2组患者血清胃蛋白酶原Ⅱ及胃泌素17水平较治疗前均明显降低、且观察组低于对照组［（16.1±3.5）μg/L比（19.8±2.4）μg/L、（15.8±2.3）pmol/L比（17.2±3.7）pmol/L］，血清胃蛋白酶原Ⅰ水平较治疗前均明显升高、且观察组高于对照组［（114±10）μg/L比（99±11）μg/L］，差异均有统计学意义（均P<0.05）。治疗后2组患者血清5-羟色胺水平较治疗前均明显升高、且观察组高于对照组，血清生长抑素水平较治疗前均明显降低、且观察组低于对照组，差异均有统计学意义（均P<0.05）。治疗后2组患者焦虑自评量表和抑郁自评量表评分均较治疗前明显降低，且观察组低于对照组，差异均有统计学意义（均P<0.05）。结论    曲美布丁联合复方阿嗪米特治疗FD患者临床效果明显，且能恢复异常的胃蛋白酶原、胃泌素、5-羟色胺和生长抑素水平。

• 【Abstract】Objective    To observe the effect of trimebutine combined with compound azintamide on pepsinogen and gastrin levels in patients with functional dyspepsia. Methods    Totally 140 patients with functional dyspepsia were enrolled from January 2017 to December 2018 in Huainan First People′s Hospital, Anhui Province. They were randomly divided into control group(65 cases) and observation group(75 cases). The control group was treated with compound azintamide. The observation group was treated with trimebutine and compound azintamide. Clinical therapeutic effect was observed. Serum levels of pepsinogen, gastrin, 5-hydroxytryptamine and somatostatin were compared before and after treatment. Results    The total effective rate in observation group was significantly higher than that in control group［90.7%（68/75） vs 72.3%（47/65）］(P<0.05). Levels of serum pepsinogen Ⅱ and gastrin 17 significantly decreased after treatment and the levels in observation group were lower than those in control group［（16.1±3.5）μg/L vs （19.8±2.4）μg/L, （15.8±2.3）pmol/L vs （17.2±3.7）pmol/L］; serum level of pepsinogen Ⅰ significantly increased after treatment and it was higher in observation group than that in control group［（114±10）μg/L vs （99±11）μg/L］(all P<0.05). After treatment, serum 5-hydroxytryptamine level significantly increased and it was higher in observation group than that in control group; serum somatostatin level significantly decreased and it was lower in observation group than that in control group(all P<0.05). After treatment, scores of Self-rating Anxiety Scale and Self-rating Depression Scale significantly decreased in both groups and the scores in observation group were lower than those in control group（all P<0.05）. Conclusion    Trimebutine combined with compound azintamide has good therapeutic effect on functional dyspepsia; it can obviously restore abnormal levels of pepsinogen, gastrin, 5-hydroxytryptamine and somatostatin.